NON-DISCLOSURE AGREEMENTNon-Disclosure Agreement • March 8th, 2024 • Column Group L P • Pharmaceutical preparations • California
This Non-Disclosure Agreement (“Agreement”), effective as of October 31, 2023 (“Effective Date”), is entered into by and between NGM Biopharmaceuticals, Inc., a Delaware corporation (“Discloser”) and The Column Group LLC (“Recipient”). Under this Agreement, Discloser may furnish certain of its confidential information to Counterparty in connection with the Counterparty’s evaluation of Discloser (“Purpose”) upon the terms and conditions set forth below.
JOINT FILING AGREEMENTJoint Filing Agreement • February 16th, 2021 • Column Group L P • Pharmaceutical preparations
The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned, and any amendments thereto executed by the undersigned shall be filed on behalf of each of the undersigned without the necessity of filing any additional joint filing agreement. The undersigned acknowledge that each is responsible for the timely filing of such statement on Schedule 13G and any amendments thereto, and for the completeness and accuracy of the information concerning him, her or it contained therein, but shall not be responsible for the completeness or accuracy of the information concerning the others of the undersigned, except to the extent that he, she or it knows or has reason to believe that such information is inaccurate or incomplete. This Joint Filing Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.
JOINT FILING AGREEMENTJoint Filing Agreement • February 16th, 2021 • Column Group L P • Pharmaceutical preparations
The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned, and any amendments thereto executed by the undersigned shall be filed on behalf of each of the undersigned without the necessity of filing any additional joint filing agreement. The undersigned acknowledge that each is responsible for the timely filing of such statement on Schedule 13G and any amendments thereto, and for the completeness and accuracy of the information concerning him, her or it contained therein, but shall not be responsible for the completeness or accuracy of the information concerning the others of the undersigned, except to the extent that he, she or it knows or has reason to believe that such information is inaccurate or incomplete. This Joint Filing Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.
JOINT FILING AGREEMENTJoint Filing Agreement • June 24th, 2020 • Column Group L P • Pharmaceutical preparations
We, the undersigned, hereby express our agreement that the attached Amendment No. 2 to Schedule 13G is filed on behalf of each of us.
JOINT FILING AGREEMENTJoint Filing Agreement • February 13th, 2019 • Column Group L P • Pharmaceutical preparations
JOINT FILING AGREEMENTJoint Filing Agreement • October 10th, 2019 • Column Group L P • Pharmaceutical preparations
ROLLOVER AGREEMENTRollover Agreement • February 26th, 2024 • Column Group L P • Pharmaceutical preparations • Delaware
This ROLLOVER AGREEMENT (this “Agreement”) is dated as of February 25, 2024, by and among (i) Atlas Neon Parent, Inc., a Delaware corporation (“Parent”), (ii) Atlas Neon Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and (iii) the Persons listed on the signature pages hereto under the heading “Sponsors” (“Sponsors” and “Holders”). Capitalized terms used but not defined herein shall have the meanings given to them in the Merger Agreement (as defined below).
ROLLOVER AGREEMENTRollover Agreement • February 26th, 2024 • Column Group L P • Pharmaceutical preparations • Delaware
This ROLLOVER AGREEMENT (this “Agreement”) is dated as of February 25, 2024, by and among (i) Atlas Neon Parent, Inc., a Delaware corporation (“Parent”), (ii) Atlas Neon Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), (iii) the Persons listed on the signature pages hereto under the heading “Sponsors” (“Sponsors”) and (iv) the Persons listed on the signature pages hereto under the heading “Additional Rollover Holders” (“Additional Holders”, and “Holders”). Capitalized terms used but not defined herein shall have the meanings given to them in the Merger Agreement (as defined below).
JOINDER AGREEMENT Dated: March 6, 2024Joinder Agreement • March 8th, 2024 • Column Group L P • Pharmaceutical preparations • Delaware
This Joinder Agreement (“Joinder Agreement”) is executed by the undersigned (“Additional Holders”), pursuant to the terms of the Rollover Agreement, dated as of February 25, 2024, a copy of which is attached hereto and is incorporated herein by reference (the “Rollover Agreement”). By the execution of this Joinder Agreement, each Additional Holder agrees as follows:
